Title
Category
Credits
Event date
Cost
  • Disease management
  • Transplantation
  • 0.75 ACPE - Pharmacists
  • 0.75 ACPE - Pharmacy Technicians
  • 0.75 AMA - Physicians
  • 0.75 ANCC - Nurses
  • 0.75 APA - Psychologists
  • 0.75 Attendance - General Attendance
  • 0.75 CCMC - General - Case Managers
  • 0.75 CDR - Dietitians
  • 0.75 ASWB - Social Workers
$0.00
This activity will examine the safety and effectiveness of SPK and islet cell transplants in reversing hypoglycemia and achieving sustained insulin independence. Current advances in SPK and islet cell transplantation will be explored, along with complications, outcomes, patient management and post-transplant monitoring. The importance of coordination between health care professionals from multiple disciplines and specialties in facilitating transplantation success will be discussed.
  • Disease management
  • Transplantation
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 CDR - Dietitians
  • 1.00 ASWB - Social Workers
$0.00
In this activity, participants will review conventional rejection-monitoring parameters and will identify current and emerging acute-rejection biomarkers. A closer look at data — regarding such biomarkers as donor-derived cell-free DNA, gene expression profiles, mRNA transcripts, immune effector pathway molecules, cell subsets and chemokines — will provide clarity about their predictive accuracy and value in rejection monitoring, as well as their ability to improve outcomes through rapid identification of transplant-organ dysfunction.
  • Covid-19
  • Disease management
  • Infectious diseases
  • Transplantation
  • 0.75 ACPE - Pharmacists
  • 0.75 ACPE - Pharmacy Technicians
  • 0.75 AMA - Physicians
  • 0.75 ANCC - Nurses
  • 0.75 APA - Psychologists
  • 0.75 Attendance - General Attendance
  • 0.75 CCMC - General - Case Managers
  • 0.75 CDR - Dietitians
  • 0.75 ASWB - Social Workers
$0.00
This activity will review the current recommendations for screening and vaccination in both organ donors and organ recipients and will examine the current rationale and value of measuring COVID-19 antibody titers in light of possible low posttransplant sero-response and humoral response rates. Importantly, the current state of, and future implications for, transplantation in nonvaccinated patients will be discussed.
  • Transplantation
  • 0.75 ACPE - Pharmacists
  • 0.75 ACPE - Pharmacy Technicians
  • 0.75 AMA - Physicians
  • 0.75 ANCC - Nurses
  • 0.75 APA - Psychologists
  • 0.75 Attendance - General Attendance
  • 0.75 CCMC - General - Case Managers
  • 0.75 CDR - Dietitians
  • 0.75 ASWB - Social Workers
$0.00
Despite the large increase in the number of multi-organ transplants (MOTs) performed over the past few years, challenges still exist in this arena. Among these unresolved issues are a lack of standardized MOT eligibility criteria across institutions, regions and different organ combinations. Ethical issues have also arisen regarding equity in organ allocation amidst a limited organ supply, as many MOT candidates get priority allocation for nonprimary organs versus individuals requiring that organ as a single transplant; this prioritization may impact optimal recipient and graft survival as well. In this session, learn more about multi-organ allocation and its accompanying challenges, risks, benefits, and expected outcomes, as well as the limitations of MOT for potential recipients.
  • Disease management
  • Transplantation
  • 0.75 ACPE - Pharmacists
  • 0.75 ACPE - Pharmacy Technicians
  • 0.75 AMA - Physicians
  • 0.75 ANCC - Nurses
  • 0.75 APA - Psychologists
  • 0.75 Attendance - General Attendance
  • 0.75 CCMC - General - Case Managers
  • 0.75 CDR - Dietitians
  • 0.75 ASWB - Social Workers
$0.00
This activity will discuss the opportunities presented by NRP to increase the availability of donor organs and allow for extended patient survival time until transplant. The principles of NRP, effects on graft survival, potential complications, and ethical and legal concerns will be reviewed.
  • Disease management
  • Transplantation
  • 0.75 ACPE - Pharmacists
  • 0.75 ACPE - Pharmacy Technicians
  • 0.75 AMA - Physicians
  • 0.75 ANCC - Nurses
  • 0.75 APA - Psychologists
  • 0.75 Attendance - General Attendance
  • 0.75 CCMC - General - Case Managers
  • 0.75 CDR - Dietitians
  • 0.75 ASWB - Social Workers
$0.00
This activity will help participants to better determine the role and optimal timing of liver transplant in ACLF. It will review precipitators of ACLF associated with poorer outcomes, including bacterial infections and hepatitis B virus, and will explore posttransplant outcomes and predictors. The accuracy of current scoring systems for assessing the severity of disease and predicting survival will be discussed, including the Model for End-stage Liver Disease (MELD) score and the Chronic Liver Failure Consortium Organ Failure (CLIF-C OF) score.
  • Disease management
  • Transplantation
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 CDR - Dietitians
  • 1.00 ASWB - Social Workers
$0.00
Join this activity to discuss how technology to treat end-stage kidney failure has advanced in recent years, including a review of clinical trials of portable devices and implantable xenotransplants, and what the future holds for the next phase of investigation into the artificial kidney and xenotransplant.
  • Disease management
  • Oncology
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 CDR - Dietitians
  • 1.00 ASWB - Social Workers
$0.00
This activty will discuss how precision medicine is quickly becoming a standard of care in the field of oncology and will explore recent advances in such applications as gene sequencing, molecular diagnostic assays, liquid biopsies and biomarkers. Future applications and innovations in precision medicine tailored to the treatment of specific cancers will also be examined.
  • Disease management
  • Oncology
  • 0.75 ACPE - Pharmacists
  • 0.75 ACPE - Pharmacy Technicians
  • 0.75 AMA - Physicians
  • 0.75 ANCC - Nurses
  • 0.75 APA - Psychologists
  • 0.75 Attendance - General Attendance
  • 0.75 CCMC - General - Case Managers
  • 0.75 CDR - Dietitians
  • 0.75 ASWB - Social Workers
$0.00
This activity will discuss these novel agents’ indications, risks, and benefits and will address which patient populations are most likely to benefit from particular agents. In addition, early-phase clinical trials and emerging therapies will be explored.
  • Disease management
  • Oncology
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 CDR - Dietitians
  • 1.00 ASWB - Social Workers
$0.00
This activity will explore the most recent advances of this rapidly evolving therapy, including current data on its efficacy, limitations and challenges in the treatment of multiple myeloma and solid tumors. It will provide an overview of currently existing guidelines for CAR T-cell therapy and will describe best practices in determining individuals’ eligibility for this type of therapy, including factors that may affect treatment efficacy and outcomes.

Pages